MG-132

For research use only.

Catalog No.S2619

1184 publications

MG-132 Chemical Structure

CAS No. 1211877-36-9

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Selleck's MG-132 has been cited by 1184 publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Targets
Proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells MVXGeY5kfGmxbjDBd5NigQ>? M3LUVVI2KM7:TR?= NEfNZ3VFVVOR NEXyU2FKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=> NH3EXYozPDZ7N{S5Oi=>
HL-60 MX7DfZRwfG:6aXOgRZN{[Xl? M1TQU|QxKM7:TR?= NIHvO4w1QCCq MWrEUXNQ MUTJR|UxRDFyIN88US=> MXOyOFY6PzR7Nh?=
SMMC-7721 NIHNOZdEgXSxdH;4bYMhSXO|YYm= MUW0NEDPxE1? MmP6OFghcA>? MVTEUXNQ M3H1cGlEPTB;Nz6xJO69VQ>? NXvHN5hVOjR4OUe0PVY>
A-549 MnO5R5l1d3SxeHnjJGF{e2G7 MXG0NEDPxE1? M{fJ[|Q5KGh? MoC2SG1UVw>? MXzJR|UxRDFyIN88US=> NF3TcmwzPDZ7N{S5Oi=>
MCF-7 NHmwU5FEgXSxdH;4bYMhSXO|YYm= M17adlQxKM7:TR?= NYO2d|MzPDhiaB?= NFu3bGtFVVOR NITuPXVKSzVyPUeuN{DPxE1? NHXyUYYzPDZ7N{S5Oi=>
SW-480 NVLDUopqS3m2b4TvfIlkKEG|c3H5 NXLBfIVnPDBizszN M17K[VQ5KGh? M{K4cWROW09? MlvkTWM2OD12IN88US=> MUOyOFY6PzR7Nh?=
NCI-H929 NFvObmxEgXSxdH;4bYMhSXO|YYm= M1fENlEh|ryP NH;YUZc4OiCq NEP6NVJFVVOR MljZTWM2OD1yLkG3JO69VQ>? NFPXSnIzPDZ{NUC4PC=>
293T MV\DfZRwfG:6aXOgRZN{[Xl? MVqxNEDPxE1? NFTK[pE4OiCq NHfCTo9FVVOR M{L5PGlEPTB:MjFOwG0> M{PJS|I1PjJ3MEi4
293T NEjERodHfW6ldHnvckBCe3OjeR?= Mn\VNVAh|ryP MkLrNlQhcA>? MnTuSG1UVw>? NW\DRZhFVW:mZYLheIVtgSCrbnT1Z4V{KGinYYStd4hw[2tiIB?= NVnTRYZ3OjR4MkWwPFg>
HeLa M{fQNGtqdmG|ZTDBd5NigQ>? M4rHWlExKM7:TR?= NFzGRm8yKGh? MXHEUXNQ Mmn5TY5lfWOnczDQRXJRKGOuZXH2ZYdmKGK7IHnubIljcXSrbnegdJJwe2Wjc3;t[UBi[3Srdnn0fS=> MnjrNlQ{OjF6M{O=
MDA-MB-231 NG\X[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDJU3dnOSEQvF2= NVWyWVJpPzJiaB?= NHHHWVlFVVOR MVHJR|UxRTBwMUig{txO MXSyOFE2OzJyNh?=
MCF-7 M1HveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOxJO69VQ>? MX23NkBp Mn7qSG1UVw>? NGPOTJBKSzVyPUCuNVMh|ryP M1rqelI1OTV|MkC2
MCF10A M17u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[2[msyKM7:TR?= MVm3NkBp M3fnZ2ROW09? MnXTTWM2OD1yLkK5JO69VQ>? MorXNlQyPTN{ME[=
HEK-293 MV3LbY5ie2ViQYPzZZk> MlfpNkBidmRiMkCg{txO MX6yJIg> NYDCZ2xrTE2VTx?= NXrVb4l1UW6qaXLpeJMhS2iWLVygZYN1cX[rdImge4l1cCCLQ{WwJI9nKDlibl2g MnTkNlM2PDB5OUC=
Calu6 NX\oTHdlTnWwY4Tpc44hSXO|YYm= NVHScXgyOTBizszN MXqxPEBp MXjEUXNQ NYfSfW9IW2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I> M2m4XFI{PTB4NEi2
IFN-gamma-induced RAW264.7 MofWSpVv[3Srb36gRZN{[Xl? NEK3T2hFVVOR MWfJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN M{C3eVIzOjd5Mke3
IPC227F NWCwOWgzS3m2b4TvfIlkKEG|c3H5 NX[0e5ZJOSEQvF2= MkPuOFghcA>? NVXXN2RnTE2VTx?= M{\XdmlEPTB;MD6wO|ch|ryP M1j0[VIyQTJ2NUK4
Hepa-1c1c7 MYrGeY5kfGmxbjDBd5NigQ>? M170c|I2KM7:TR?= MUm2JIg> NHHkR2NFVVOR NHS0UFhKdmO{ZXHz[ZMhVnKoMjDwdo91\WmwIHzleoVt MVuyNFM6OjV2NB?=
COS-7 MUnDfZRwfG:6aXOgRZN{[Xl? M{f1bFExKM7:TR?= NYO5cnJSTE2VTx?= M3X3SGlEPTB:MUCg{txO NF3FOWIyQDB6OEC5Oy=>
HuH-7 MXfDfZRwfG:6aXOgRZN{[Xl? M3XkblExKM7:TR?= NUnoU5BOTE2VTx?= MWTJR|UxRDFyIN88US=> M2PMfVE5ODh6MEm3
OCI-Ly3 NULDRYd5TnWwY4Tpc44hSXO|YYm= NV;mbpE6OTBizszNxsA> MVS0JIg> NVToNFJ7TE2VTx?= MXfJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>? NFm1c5EyQDB{NEGxNy=>
A2780 cDDP NWDicYhISXCxcITvd4l{KEG|c3H5 MmjHNlQhcA>? NEfPUXJFVVOR MYfJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44> M2TUbFE4Pjh2MEG4
LPS-stimulated RAW264.7 cells MlnkSpVv[3Srb36gRZN{[Xl? MXvEUXNQ MlnrTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o MWexO|QxPzJ5Nx?=
PC12 MVTGeY5kfGmxbjDBd5NigQ>? M2nqe|ExOCEQvF5CpC=> NHv3V3QzPCCq NFPvXZlFVVOR MVXJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5 NEfTfGIyPzF3OES1OC=>
PC3 NYq3NYdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTXSpRzOjBizszN NH3VUZI1QCCq NXnpbXJbTE2VTx?= MXTJR|UxRTBwNjFOwG0> NIrIS|MyPjZ6NkWzOy=>
LP-1 MkDjRZBweHSxc3nzJGF{e2G7 M3vrZlMxOCCwTR?= Mof0NlQhcA>? Mor2SG1UVw>? MlX4TY5lfWOnczDhdI9xfG:|aYOgZpkhcW6lcnXhd4lv\yClbHXheoVlKFCDUmCgcIV3\WxiYX7kJJJm\HWlaX7nJG1kdC1zIIDyc5RmcW5ibHX2[Yw> NWjESVU6OTV7NUi1PFk>
ES6 NWjxNXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ST2lEPTB;MD6wNVMxPiEQvF2= MmLsV2FPT0WU
A101D NGPlOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjPN2RuUUN3ME2wMlA{Ojd7IN88US=> MU\TRW5ITVJ?
OCUB-M NX;hUIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHVTWM2OD1yLkCzO|M4KM7:TR?= M3X3PXNCVkeHUh?=
LB2518-MEL M4LPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjUZ41IUUN3ME2wMlA{PzZizszN Ml;YV2FPT0WU
SH-4 M3;USWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXuOXBKSzVyPUCuNFQ{OSEQvF2= NUjHV3RrW0GQR1XS
KNS-42 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHtTZZKSzVyPUCuNFQ1PDFizszN NEjmOYRUSU6JRWK=
DSH1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPUNHF6UUN3ME2wMlA2Ojh7IN88US=> MUjTRW5ITVJ?
NTERA-S-cl-D1 NXjqUlJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTTTWM2OD1yLkC1O|czKM7:TR?= M1vrfHNCVkeHUh?=
D-542MG NHfmSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEW5OVch|ryP NWm2UGNnW0GQR1XS
KS-1 M4H6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfoTWM2OD1yLkC2OFU5KM7:TR?= Mk[yV2FPT0WU
BL-41 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnwTWM2OD1yLkC2PVQ4KM7:TR?= NIDYPZZUSU6JRWK=
LXF-289 M3vYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEewOlYh|ryP MVzTRW5ITVJ?
D-247MG NGewSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPMXo1mUUN3ME2wMlA4OjB7IN88US=> M2DtWHNCVkeHUh?=
MMAC-SF M1vMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW5cFdKSzVyPUCuNFczPjhizszN NVPrcHJmW0GQR1XS
CP66-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf1[lRKSzVyPUCuNFc2KM7:TR?= MWfTRW5ITVJ?
LB771-HNC MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPIW21KSzVyPUCuNFgxOzZizszN NI\KSZNUSU6JRWK=
no-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT4OZdoUUN3ME2wMlA5QTB7IN88US=> NE\0fZhUSU6JRWK=
A388 NHLGcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHGTWM2OD1yLkC5NFY2KM7:TR?= NXrxTJdDW0GQR1XS
OPM-2 NVS4cFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTxR5hKSzVyPUCuNVA1PzRizszN NH3oNYtUSU6JRWK=
OVCAR-4 NELrdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLXWlEPTB;MD6xNFk{QCEQvF2= NGL2VFZUSU6JRWK=
HOP-62 M4GzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnlWWtKSzVyPUCuNVA6PDlizszN M{LFfXNCVkeHUh?=
ML-2 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf1TWM2OD1yLkGxPFA3KM7:TR?= MnTYV2FPT0WU
UACC-257 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknGTWM2OD1yLkGxPVI4KM7:TR?= M2O4XnNCVkeHUh?=
NEC8 NWLPPGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULlVZFLUUN3ME2wMlEyQTl3IN88US=> M16wO3NCVkeHUh?=
ONS-76 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u0eWlEPTB;MD6xNlk{PSEQvF2= MlXiV2FPT0WU
KE-37 NWTj[JRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUOyO|gh|ryP NUDTeWpqW0GQR1XS
HT-144 NIfl[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO5dpRKSzVyPUCuNVM5QTVizszN M{[2b3NCVkeHUh?=
LB2241-RCC NXn5O442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;KRWlEPTB;MD6xOFI1PyEQvF2= MnnVV2FPT0WU
TE-5 NX7x[pdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrNZWpUUUN3ME2wMlE1Ojd6IN88US=> MmizV2FPT0WU
KINGS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\NcVdKSzVyPUCuNVQ4QSEQvF2= MX3TRW5ITVJ?
NCI-H69 MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXDNplKSzVyPUCuNVUyPDFizszN M{\XS3NCVkeHUh?=
CAS-1 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMUW0PFIh|ryP M1ez[nNCVkeHUh?=
D-263MG MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMU[wNFYh|ryP NIrDNIJUSU6JRWK=
A253 M{HXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMU[xNlgh|ryP NF7DWXdUSU6JRWK=
PF-382 MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnrTWM2OD1yLkG2O|A3KM7:TR?= MofrV2FPT0WU
CESS MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne1TWM2OD1yLkG3NFYh|ryP NIO3dIxUSU6JRWK=
MZ2-MEL NGXlSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nnUmlEPTB;MD6xO|U2QSEQvF2= NEXnOlBUSU6JRWK=
HEL NX7Je3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm5TWM2OD1yLkG4OVE4KM7:TR?= MYXTRW5ITVJ?
D-392MG NGnNT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf2TWM2OD1yLkG5NVE2KM7:TR?= NGHKO49USU6JRWK=
SK-LMS-1 M{\FZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHUepdUUUN3ME2wMlE6OzB|IN88US=> NY\OclFuW0GQR1XS
GI-ME-N NEC3d3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMUmzNFYh|ryP NITZfFJUSU6JRWK=
LB831-BLC MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LHVGlEPTB;MD6xPVM1KM7:TR?= MofvV2FPT0WU
DU-4475 NVO5V5k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfnbYg5UUN3ME2wMlE6PjV6IN88US=> NYrhSlN3W0GQR1XS
IST-SL1 NXfNNIhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[wTWM2OD1yLkKwNFk1KM7:TR?= MV;TRW5ITVJ?
GAK M2XlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvoUZM5UUN3ME2wMlIxPTN2IN88US=> MmjXV2FPT0WU
EW-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qxdWlEPTB;MD6yNVA1PyEQvF2= NHvRS4dUSU6JRWK=
LAMA-84 NXvqNXdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrXOI1KSzVyPUCuNlE5PTFizszN NXXlRWpHW0GQR1XS
SK-UT-1 NYfJ[WRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHZTHA{UUN3ME2wMlIzODR7IN88US=> M1nzdXNCVkeHUh?=
VA-ES-BJ NIrWbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMkKyOVch|ryP MXXTRW5ITVJ?
ACN NVq1WGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMkK2N|gh|ryP MmO0V2FPT0WU
SK-PN-DW M1Ttemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13tc2lEPTB;MD6yN|E6KM7:TR?= NE[wWXBUSU6JRWK=
HD-MY-Z Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHidHI4UUN3ME2wMlI{OzB|IN88US=> MXvTRW5ITVJ?
LB373-MEL-D MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfsTWM2OD1yLkK0NVk5KM7:TR?= NFXJS3dUSU6JRWK=
COLO-829 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7JTWM2OD1yLkK0NlU4KM7:TR?= M33tdnNCVkeHUh?=
ES8 NV;HdHFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnsTWM2OD1yLkK0O|Y{KM7:TR?= MVLTRW5ITVJ?
RXF393 M{XIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvVV2xTUUN3ME2wMlI2ODF3IN88US=> NX7zXJhXW0GQR1XS
TK10 NVLUPIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHhTWM2OD1yLkK1OFM2KM7:TR?= MkTPV2FPT0WU
LOUCY NVHOSnpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[1S2lEPTB;MD6yOVQ2PiEQvF2= M3HXdnNCVkeHUh?=
MZ7-mel MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4roRmlEPTB;MD6yOlM4PCEQvF2= NFHhe4FUSU6JRWK=
CP67-MEL NWf4ZYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3hTWM2OD1yLkK2O|Mh|ryP M{H0T3NCVkeHUh?=
C2BBe1 M4niNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XRemlEPTB;MD6yO|kxPyEQvF2= NHLzTVVUSU6JRWK=
K052 Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TjemlEPTB;MD6yPFk6KM7:TR?= MX3TRW5ITVJ?
MOLT-16 M{\UeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrjN4VKSzVyPUCuNlk2OjRizszN NVHDVYhtW0GQR1XS
KNS-81-FD M2SzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{CzNlMh|ryP MXXTRW5ITVJ?
CMK NWTQ[4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTBPXVKSzVyPUCuN|EyOiEQvF2= NVXTfHB7W0GQR1XS
LAN-6 NWHZNXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LTZ2lEPTB;MD6zNVMh|ryP MXfTRW5ITVJ?
KLE MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7SSmdiUUN3ME2wMlMyOzB4IN88US=> NVm2e2lqW0GQR1XS
NCCIT M3HIRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnheJdsUUN3ME2wMlMyPzh|IN88US=> MVPTRW5ITVJ?
HH M3\QNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\0dIZKSzVyPUCuN|I5QTdizszN NEeySnpUSU6JRWK=
TE-8 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwM{SyO|kh|ryP MWPTRW5ITVJ?
GDM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfVTWM2OD1yLkO1NVA1KM7:TR?= Mmm0V2FPT0WU
NCI-H747 M1\SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XwNGlEPTB;MD6zO|ExOyEQvF2= MkHUV2FPT0WU
NCI-H1092 M2rnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLQSGppUUN3ME2wMlM5QDR2IN88US=> MkfBV2FPT0WU
8-MG-BA MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;PTWM2OD1yLkO5PFM4KM7:TR?= MlzZV2FPT0WU
NB17 NWCyc|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPifXBKSzVyPUCuOFI6PyEQvF2= NF[yUmJUSU6JRWK=
LC4-1 M3uzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ny[2lEPTB;MD60N|YxPyEQvF2= MYrTRW5ITVJ?
TE-1 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH3T5VKSzVyPUCuOFUyOTlizszN MWfTRW5ITVJ?
KALS-1 NVnjeIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwNE[1PFQh|ryP NGrzSYlUSU6JRWK=
CCRF-CEM NIfsOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPLNmp[UUN3ME2wMlQ4Pjd2IN88US=> NVHIPJRYW0GQR1XS
OS-RC-2 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNEe5O|Ih|ryP M3z5THNCVkeHUh?=
A704 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGeyXJpKSzVyPUCuOFg3QTJizszN NETs[5JUSU6JRWK=
BB49-HNC NEPyOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPJTWM2OD1yLkS5NFk3KM7:TR?= MoD0V2FPT0WU
EVSA-T NWewR49ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNEm5NVEh|ryP MXXTRW5ITVJ?
Mo-T NGXnN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TE[WlEPTB;MD61NVc3OiEQvF2= NFrPS4NUSU6JRWK=
MONO-MAC-6 NH7RTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjPfVFmUUN3ME2wMlU{PjFzIN88US=> NFrWW49USU6JRWK=
BB65-RCC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rtdWlEPTB;MD61OlgyOSEQvF2= NXvRNlB[W0GQR1XS
NCI-H1882 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XjZmlEPTB;MD61PVA{PiEQvF2= NWf5SGs{W0GQR1XS
TE-9 M2Tzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfrbG5KSzVyPUCuOlExOzNizszN MlnVV2FPT0WU
NCI-H2126 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfhTWM2OD1yLk[yOlY6KM7:TR?= MUTTRW5ITVJ?
SF268 NVzOcoFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTrTWM2OD1yLk[1OlQyKM7:TR?= NVTYRlFlW0GQR1XS
SW872 M1mwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyfIVKSzVyPUCuOlU4OjlizszN M36yTnNCVkeHUh?=
LS-513 NVHGfoZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSe2JKSzVyPUCuOlY4PTFizszN NXHUSHZLW0GQR1XS
NCI-H1355 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnLTWM2OD1yLk[4OlE6KM7:TR?= MorkV2FPT0WU
BL-70 NV7pU3Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwNkmzPFgh|ryP MWXTRW5ITVJ?
NCI-SNU-5 NYDwfm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDPbYVKSzVyPUCuOlk2PDVizszN NVSxPZlMW0GQR1XS
SNU-C2B M3nzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwN{C3N|kh|ryP M361V3NCVkeHUh?=
GB-1 NFTZO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHuTWM2OD1yLkeyNVI1KM7:TR?= Mle0V2FPT0WU
CTB-1 NF7nZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XjdWlEPTB;MD63O|k2PSEQvF2= MULTRW5ITVJ?
Becker MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLEd5c5UUN3ME2wMlc6PjJzIN88US=> Mnq4V2FPT0WU
KM12 M{Lkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rGcGlEPTB;MD64OVQ3PiEQvF2= MXPTRW5ITVJ?
ES7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PLTGlEPTB;MD64PVY2KM7:TR?= M16xcXNCVkeHUh?=
COLO-684 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfYNnV4UUN3ME2wMlkxPjV6IN88US=> NH3GW|FUSU6JRWK=
HCC2998 NVK2bpAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvwXJlKSzVyPUCuPVM5PTRizszN NEXZ[3hUSU6JRWK=
TE-10 M3W0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO1TWM2OD1yLkm2OFMh|ryP MW\TRW5ITVJ?
SF126 NXi4U5ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfFUHFKSzVyPUCuPVg6PzFizszN NYXPXIV5W0GQR1XS
EKVX MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PKU2lEPTB;MT6wN|Q1OiEQvF2= NYfKWoxYW0GQR1XS
KARPAS-45 NXLVZY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHwSo5KSzVyPUGuNFQxOTZizszN NYjBSIZ1W0GQR1XS
KGN NF\MeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPl[npKSzVyPUGuNFUxPDVizszN Ml7jV2FPT0WU
ES1 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPHe|h6UUN3ME2xMlA4QTJzIN88US=> NYD2W2IyW0GQR1XS
L-540 NFKyTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFwMUG4N|kh|ryP MULTRW5ITVJ?
KURAMOCHI M2nZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPreVlKSzVyPUGuNVI{PzRizszN MVvTRW5ITVJ?
LU-65 M2rCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH6TWM2OD1zLkGyO|U{KM7:TR?= MVPTRW5ITVJ?
MFH-ino MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfWem9KSzVyPUGuNVc2ODFizszN NInCXHRUSU6JRWK=
NCI-H23 NXK5dmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fldmlEPTB;MT6yNFQyKM7:TR?= MoTkV2FPT0WU
IA-LM M{Dr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4UVBlUUN3ME2xMlI1OTF4IN88US=> MnfXV2FPT0WU
PSN1 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX4eI81UUN3ME2xMlI4ODF4IN88US=> MX;TRW5ITVJ?
NCI-H719 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfWcGlKSzVyPUGuNlc1OTFizszN MnL1V2FPT0WU
SW684 NEXKdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzabIlKSzVyPUGuNlg3PTlizszN MX;TRW5ITVJ?
HCE-4 NFvNNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\xUZlKSzVyPUGuN|AzOjFizszN NULtVIdtW0GQR1XS
EW-16 NUTKUlRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\vXnlKSzVyPUGuN|E{PDdizszN MYfTRW5ITVJ?
NCI-H128 M3y5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwM{W4NVQh|ryP MUHTRW5ITVJ?
HC-1 NUnE[pBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTVTWM2OD1zLkO4NVch|ryP NUiz[IozW0GQR1XS
IST-MES1 NEnRdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jXeWlEPTB;MT60NFIxQCEQvF2= NIPxdohUSU6JRWK=
Raji NX31XIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwNEG4OUDPxE1? MlKzV2FPT0WU
DMS-114 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwNES1N|kh|ryP NWjufWhzW0GQR1XS
GI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGye4dKSzVyPUGuOFcyOzFizszN NF\2R|BUSU6JRWK=
NCI-H2081 NUHFc3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwNUWxPVYh|ryP MYPTRW5ITVJ?
LC-1F MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3US|FRUUN3ME2xMlU2OTl6IN88US=> NEf4UWtUSU6JRWK=
NCI-H2227 NUjTT4s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfudnNKSzVyPUGuOlE2PjFizszN NIi3OVhUSU6JRWK=
D-502MG MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwNkeyNVEh|ryP M3nIO3NCVkeHUh?=
NCI-H2141 NGrsS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3MV3pKSzVyPUGuOlc{OTdizszN NUPlOphpW0GQR1XS
LS-411N NW\lSWNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwNkm4NFch|ryP NIHtfHZUSU6JRWK=
SU-DHL-1 NFfuRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW0TWM2OD1zLkexNlgyKM7:TR?= NEfTRY1USU6JRWK=
BB30-HNC MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3MTWM2OD1zLkeyOlg2KM7:TR?= MVfTRW5ITVJ?
TE-15 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rVfWlEPTB;MT65NlM4OyEQvF2= NFW1WXFUSU6JRWK=
JVM-3 NGHt[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TteGlEPTB;MT65N|kxPCEQvF2= NGXVeVNUSU6JRWK=
IST-SL2 NHHYPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj2TIRKSzVyPUKuNFEzPTJizszN M4PWWnNCVkeHUh?=
EW-18 NHLGdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPoTWM2OD1{LkCyN|M4KM7:TR?= MV\TRW5ITVJ?
DJM-1 NX[ydYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP4RpJKSzVyPUKuNFI2PTJizszN NXTMOVdHW0GQR1XS
no-11 M2LnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwMEOxNFQh|ryP NHu1NWJUSU6JRWK=
QIMR-WIL NHnRUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXNVZdZUUN3ME2yMlE3PzZ{IN88US=> NUf5bFNxW0GQR1XS
MC-CAR NVruVIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDnOHNKSzVyPUKuNlI6PSEQvF2= MYTTRW5ITVJ?
KM-H2 NYrJWFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHMc|BvUUN3ME2yMlI6ODR|IN88US=> MmTDV2FPT0WU
ECC12 NYXOVXJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwM{e5OEDPxE1? NYq2RnB4W0GQR1XS
HCE-T MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLJdopKSzVyPUKuOFQ5QDNizszN MlXuV2FPT0WU
MFM-223 NVThcIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjGUlZpUUN3ME2yMlUxQDdzIN88US=> MV3TRW5ITVJ?
SW982 M1KyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDk[IJKSzVyPUKuOVE1QCEQvF2= NVXsfY45W0GQR1XS
KG-1 M1nudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ySIlKSzVyPUKuPFg4QTFizszN M4C3WXNCVkeHUh?=
ES4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNwME[xNVEh|ryP NWj5SoNkW0GQR1XS
SCC-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHj[GZKSzVyPUOuNVA5PDhizszN M17qNHNCVkeHUh?=
RH-1 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LBZWlEPTB;Mz6zPFc1QCEQvF2= M{S2WXNCVkeHUh?=
NCI-H748 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tz[WlEPTB;Mz60OFI3PiEQvF2= MnO1V2FPT0WU
HCC2218 NFfndVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\LTWM2OD1|LkS2PVM4KM7:TR?= M{WzN3NCVkeHUh?=
MEG-01 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\lT|JiUUN3ME2zMlU6PjhizszN NG\i[o5USU6JRWK=
NB12 NIPJfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\JNJZCUUN3ME2zMlU6QDh6IN88US=> NIPNbolUSU6JRWK=
SNB75 NHjNV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwNkCxNFMh|ryP MkXtV2FPT0WU
KMS-12-PE M3r3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjkTGJKSzVyPUOuOlc4OjNizszN MYDTRW5ITVJ?
SKM-1 NYjqPW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O3WGlEPTB;Mz63NVM4PiEQvF2= MVPTRW5ITVJ?
COLO-320-HSR NYLvOGRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T6d2lEPTB;Mz63OVY{PCEQvF2= MVXTRW5ITVJ?
NKM-1 M4PnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDsbpNKSzVyPUOuO|c{PzhizszN MVPTRW5ITVJ?
TE-6 NGTjdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwOUS1OlEh|ryP MmXvV2FPT0WU
D-336MG M1j3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzOGlEPTB;ND6wNVE3PiEQvF2= NHrrcGNUSU6JRWK=
NCI-H1650 M{fmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PqOGlEPTB;ND6xOVc6PyEQvF2= MXXTRW5ITVJ?
ES3 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0PG5LUUN3ME20MlMzQDJ2IN88US=> NHTMe3RUSU6JRWK=
YT NG\lcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPjRY5KSzVyPUSuN|U1OjRizszN MknDV2FPT0WU
ES5 M1LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRXGlEPTB;ND60NFI2PSEQvF2= M{ezNnNCVkeHUh?=
LB647-SCLC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PjfGlEPTB;ND61OlMxQCEQvF2= MX3TRW5ITVJ?
HAL-01 NXHhcpBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRwNUewN|Qh|ryP NX;xZ5JSW0GQR1XS
LP-1 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTRwN{KzO|Eh|ryP NHzFRVFUSU6JRWK=
BC-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwMEC0OFch|ryP NUPuWGNQW0GQR1XS
EB-3 M17UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTVwMEOwOFEh|ryP NFyxR45USU6JRWK=
GT3TKB M3vrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nq[2lEPTB;NT6xO|Y3OiEQvF2= NEDoUZpUSU6JRWK=
NCI-H209 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnsTWM2OD13LkG5N|UzKM7:TR?= MVvTRW5ITVJ?
BT-474 NH7jR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTVwMkOxNFIh|ryP MWnTRW5ITVJ?
RKO NIjCUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTDUFRKSzVyPUWuNlM1OjJizszN MnPaV2FPT0WU
SIMA M3\HR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwM{C3OlUh|ryP M4e4XXNCVkeHUh?=
RL NUC4XYpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;STWM2OD13LkO3OVQyKM7:TR?= MkT6V2FPT0WU
GCIY MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\xR4dKSzVyPUWuOFczOzZizszN NHT4TYZUSU6JRWK=
Calu-6 M4rOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzRlJKSzVyPUWuOlIzKM7:TR?= NXTrZXZiW0GQR1XS
ALL-PO NVe4b5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P4WGlEPTB;NT62N|c6PSEQvF2= MUjTRW5ITVJ?
ARH-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfYe2x{UUN3ME21MlY4ODh5IN88US=> MnrPV2FPT0WU
A4-Fuk NVrUUm1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf0VWF6UUN3ME22MlA5OTF6IN88US=> NEn4VohUSU6JRWK=
NCI-H1581 NGW0O5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor3TWM2OD14LkKzPFQ6KM7:TR?= NVXyc|g2W0GQR1XS
HUTU-80 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXjTWM2OD14LkO2PFk4KM7:TR?= NV7hdGVFW0GQR1XS
TGW NXTLVmVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLE[|dKSzVyPU[uOFU2QTNizszN NF3jU|JUSU6JRWK=
SK-N-FI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonBTWM2OD14LkS1PFU1KM7:TR?= NVW4NG97W0GQR1XS
U-266 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmxTWM2OD14LkWxPVI3KM7:TR?= NEHZTlNUSU6JRWK=
EM-2 NFHUdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfCVmhMUUN3ME22MlY4ODl7IN88US=> M3PXOHNCVkeHUh?=
NMC-G1 NFLDbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXvenA1UUN3ME22MlcyQDl3IN88US=> NGLTbpJUSU6JRWK=
KASUMI-1 M{fIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn4S5pKSzVyPU[uPFQ4QDdizszN NIfnSGlUSU6JRWK=
NALM-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwOE[3OVQh|ryP NV7lOmd1W0GQR1XS
OCI-AML2 NWCzd2NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjjXGdKSzVyPUeuNFA{OjZizszN MkDXV2FPT0WU
SHP-77 NG\IOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\yRWlEPTB;Nz6yNlQ{KM7:TR?= MXXTRW5ITVJ?
NOMO-1 NXLmTVUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\lXmRFUUN3ME23MlI1OjV2IN88US=> M17HUnNCVkeHUh?=
SK-N-DZ M3racmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPtTWM2OD15LkexNFg6KM7:TR?= Mo\TV2FPT0WU
LB1047-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLKSIpKSzVyPUeuO|IzOzFizszN NFTF[5hUSU6JRWK=
MZ1-PC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljCTWM2OD15Lki2OVU5KM7:TR?= NEiyRnpUSU6JRWK=
NB10 NFGyboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ezN2lEPTB;Nz65PVU2PiEQvF2= M{f6bnNCVkeHUh?=
RL95-2 NWLOV4t6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LoXGlEPTB;OD6xNFg1OiEQvF2= MVvTRW5ITVJ?
OMC-1 NV3yepRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETwd5NKSzVyPUiuOVIyQTFizszN NVTwRY54W0GQR1XS
D-283MED MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;3cHlKSzVyPUiuPVE4OTlizszN NVvq[XNUW0GQR1XS
MC116 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLaTWM2OD16Lkm3PVQh|ryP MlWxV2FPT0WU
SJSA-1 M1TqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2riTmlEPTB;OT6wPVA6OSEQvF2= MlS5V2FPT0WU
JiyoyeP-2003 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1izTmlEPTB;OT6yPVMyPyEQvF2= MlrLV2FPT0WU
IST-MEL1 NVTtRoVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HiN2lEPTB;OT63OFE6QCEQvF2= MUfTRW5ITVJ?
CTV-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rjV2lEPTB;MUCuNFk4QSEQvF2= NHjLU2NUSU6JRWK=
NH-12 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFyLkK0N|Mh|ryP NHPxR4VUSU6JRWK=
CA46 NYDC[5hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPn[m9KSzVyPUGwMlM3OSEQvF2= NXPoOot[W0GQR1XS
NCI-SNU-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfOR3UzUUN3ME2xNE41QTZ7IN88US=> MmTJV2FPT0WU
SCLC-21H MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fhcWlEPTB;MUCuOlU6PiEQvF2= MlfoV2FPT0WU
EC-GI-10 NUj6[pNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4TWM2OD1zMD63NFMyKM7:TR?= Ml;hV2FPT0WU
SR Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[zPGZnUUN3ME2xNU4xOTh3IN88US=> NUP1TGVuW0GQR1XS
NCI-H1648 M1nWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K5PWlEPTB;MUGuNFk3PSEQvF2= Mkj4V2FPT0WU
TGBC1TKB NXWwT5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\LTWM2OD1zMT60NVAzKM7:TR?= M13EU3NCVkeHUh?=
EW-11 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFzLkWxPFYh|ryP M37DeXNCVkeHUh?=
SK-MM-2 NH33NpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzCTWM2OD1zMT64NFYyKM7:TR?= MXvTRW5ITVJ?
NCI-H524 NHHkTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SzSmlEPTB;MUGuPVgzOiEQvF2= Mn3RV2FPT0WU
NOS-1 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXtNYh1UUN3ME2xNk4xOzR3IN88US=> MnLWV2FPT0WU
AM-38 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTkTWM2OD1zMj61OlM{KM7:TR?= MX\TRW5ITVJ?
A498 NXnFOXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF{LkewOlkh|ryP M2XCOnNCVkeHUh?=
KARPAS-422 M3SwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF{Lke0PVYh|ryP NYD5NWFyW0GQR1XS
LU-139 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17KdGlEPTB;MUKuPVAzPiEQvF2= MYnTRW5ITVJ?
COR-L88 NEfOT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\qeppKSzVyPUGyMlk{QDJizszN NWHC[2ZoW0GQR1XS
K5 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nxT2lEPTB;MUKuPVQ3OiEQvF2= NVi5bGFKW0GQR1XS
NB13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPRTWM2OD1zMj65O|g{KM7:TR?= MornV2FPT0WU
MRK-nu-1 NUfjPVRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF|LkG5OUDPxE1? NVnpO2s4W0GQR1XS
MHH-NB-11 M3mz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF|LkK5NFIh|ryP NWTxVYpEW0GQR1XS
KU812 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3iyfWlEPTB;MUOuOlEzPCEQvF2= MkG0V2FPT0WU
TE-12 NUL0e2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT2eVJTUUN3ME2xN{43QTl2IN88US=> MljTV2FPT0WU
NCI-N87 MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF|LkezOkDPxE1? NYXMdmoyW0GQR1XS
EB2 NU\IXHJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECyb2JKSzVyPUGzMlg2ODVizszN NIrGVFZUSU6JRWK=
DB NFPQSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLHbFRKSzVyPUGzMlk5QDVizszN NELJS5lUSU6JRWK=
697 M2rSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETl[JFKSzVyPUG0MlQ2OTFizszN NGC0RXJUSU6JRWK=
MSTO-211H M1vOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF2Lke0OFgh|ryP NHLUemxUSU6JRWK=
JVM-2 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ju[mlEPTB;MUSuO|c{PSEQvF2= NE\x[pRUSU6JRWK=
COLO-824 NWfr[|R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4XHRRUUN3ME2xOE44QTl2IN88US=> MUTTRW5ITVJ?
BC-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPCVG1KSzVyPUG1MlM6QCEQvF2= M1HK[nNCVkeHUh?=
BOKU NVTjN2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF3Lkm2NFgh|ryP MlPlV2FPT0WU
GOTO MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PnSGlEPTB;MU[uPVYyPyEQvF2= MYnTRW5ITVJ?
HCC2157 NWLzZ|hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjESIdGUUN3ME2xO{41PzV3IN88US=> M2CxV3NCVkeHUh?=
LS-1034 M{DOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYntNpF3UUN3ME2xO{43QDF6IN88US=> MkjpV2FPT0WU
CAL-148 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jPR2lEPTB;MUeuPVc6PiEQvF2= MWjTRW5ITVJ?
MOLT-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF6LkiyNFgh|ryP MY\TRW5ITVJ?
Daudi NVXtXpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF6LkmyN|Eh|ryP NYTQd|R3W0GQR1XS
J-RT3-T3-5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqxVmdKSzVyPUG5MlQxPjZizszN NUDkW4RIW0GQR1XS
KMOE-2 M4DP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW5TWM2OD1zOT62OFgzKM7:TR?= MoHOV2FPT0WU
HL-60 NYOxUoV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXLbWpKSzVyPUKwMlE6PjVizszN Mlr3V2FPT0WU
P31-FUJ NGrWfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS0TWM2OD1{MD60O|U{KM7:TR?= Mk[0V2FPT0WU
IM-9 NXP5Unp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\mTWM2OD1{MD62NlI1KM7:TR?= M{fNPHNCVkeHUh?=
HDLM-2 NXjRTphbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i1[2lEPTB;MkCuPFgzOSEQvF2= M{O4e3NCVkeHUh?=
NCI-H1304 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjUfWNKSzVyPUKxMlA{OTFizszN NFi3VFRUSU6JRWK=
NCI-H345 M3HIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfXTWM2OD1{MT6wOlQ{KM7:TR?= NVnuUnhEW0GQR1XS
RPMI-6666 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnEOI5HUUN3ME2yNU4{PjB{IN88US=> M3n4ZXNCVkeHUh?=
GR-ST MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTETWM2OD1{MT60NVch|ryP Mo\QV2FPT0WU
CHP-126 NIDQWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJzLk[xPFEh|ryP NWjiclFQW0GQR1XS
EHEB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX1PJNMUUN3ME2yNU43PzNzIN88US=> M4n4SHNCVkeHUh?=
CPC-N NVj2VGxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ2LkCyNFEh|ryP Mme3V2FPT0WU
NB1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXGfIdiUUN3ME2yOE43QTN7IN88US=> M2i2fHNCVkeHUh?=
LS-123 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DLN2lEPTB;MkSuPVAyOiEQvF2= NGHWelhUSU6JRWK=
ST486 NEnZN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qyTGlEPTB;MkWuNVEyOyEQvF2= MYHTRW5ITVJ?
NCI-H1963 NVuyfog1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTUTWM2OD1{Nj6wOlI{KM7:TR?= NIe4NWtUSU6JRWK=
U-87-MG M3flTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TiOGlEPTB;Mk[uO|Y1PCEQvF2= M1fjZXNCVkeHUh?=
COR-L279 NHjTflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ4Lke5NlIh|ryP MXfTRW5ITVJ?
LU-165 M{[wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX3TWM2OD1{OD6wPFYyKM7:TR?= NXnwV5hpW0GQR1XS
COLO-800 NG\2cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X5RmlEPTB;MkiuNlk2PiEQvF2= M1znVXNCVkeHUh?=
ETK-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTZTWM2OD1{OD6zOFQ3KM7:TR?= NF7IPWJUSU6JRWK=
LNCaP-Clone-FGC Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ7LkmyPFEh|ryP NXLaPYQxW0GQR1XS
SIG-M5 M1j0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjZNZlRUUN3ME2zNE44QTV{IN88US=> NIXDNXZUSU6JRWK=
NB6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvTXm9KSzVyPUOwMlk2ODNizszN MlH6V2FPT0WU
NCI-H2107 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfEN2FKSzVyPUOxMlI{OzhizszN MmjKV2FPT0WU
SNU-C1 NVq5bJJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:4TWM2OD1|MT6zNVI3KM7:TR?= MYjTRW5ITVJ?
JAR NX3QSJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjqZ4NKSzVyPUOxMlM4QTlizszN MkfOV2FPT0WU
L-363 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2wSmRKSzVyPUOyMlIyPDRizszN MmW0V2FPT0WU
EW-24 NXezZpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe5WG5KSzVyPUOyMlM1PzRizszN M{HTSXNCVkeHUh?=
NB69 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfkNFhKSzVyPUOzMlY1PTRizszN NUDjUlBFW0GQR1XS
EW-13 M3vyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN|Lki5Olkh|ryP NIrwd2tUSU6JRWK=
Ramos-2G6-4C10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN2LkK5PVMh|ryP NHXzRVJUSU6JRWK=
TE-11 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\2PGlEPTB;M{SuOFgzOiEQvF2= MXXTRW5ITVJ?
L-428 NEHnRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\qTWM2OD1|ND63OVM3KM7:TR?= NIXjVIxUSU6JRWK=
KP-N-YN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTN2LkmwOVch|ryP NG\ac5FUSU6JRWK=
CGTH-W-1 NEnVfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHpOoZDUUN3ME2zOk46ODR6IN88US=> MUHTRW5ITVJ?
K-562 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvmWIJKSzVyPUO3MlA5PjRizszN NGeyTGhUSU6JRWK=
NCI-H1299 NFL0O5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nYe2lEPTB;M{iuNVYxOyEQvF2= NYPCU21JW0GQR1XS
RCC10RGB NX7teGJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSxTWM2OD1|OD6yNFg{KM7:TR?= NH;rRZdUSU6JRWK=
NCI-SNU-16 NV[wVo1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;VdmlEPTB;M{iuOVY2OyEQvF2= M3LRZXNCVkeHUh?=
LC-2-ad MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN7LkSzN|ch|ryP MXjTRW5ITVJ?
MHH-PREB-1 NFLmToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\xUJRsUUN3ME2zPU44Ozh6IN88US=> Ml7SV2FPT0WU
NCI-H64 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO5TWM2OD12MD6wPVQ5KM7:TR?= MV7TRW5ITVJ?
LB996-RCC NH3iNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzPb21pUUN3ME20NE45PzF4IN88US=> MofZV2FPT0WU
DEL M1Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jJ[2lEPTB;NEGuOFQxPSEQvF2= NIjwUHNUSU6JRWK=
MLMA MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O5NWlEPTB;NEGuO|U6PSEQvF2= NHTFfHZUSU6JRWK=
SBC-1 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\HTWM2OD12Mj6xPFA3KM7:TR?= NGfESXJUSU6JRWK=
MPP-89 MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvTWM2OD12Mj61PFc2KM7:TR?= MkDMV2FPT0WU
MV-4-11 MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnsTWM2OD12Mj65NFY4KM7:TR?= Mn;SV2FPT0WU
EoL-1- M3yzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLITWM2OD12ND6xOVY5KM7:TR?= M33ubnNCVkeHUh?=
CW-2 NGLRbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR2LkizOFIh|ryP M1jYSnNCVkeHUh?=
HT MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\6TWM2OD12NT63NFA4KM7:TR?= NEDp[VNUSU6JRWK=
SW954 M4fxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzRSop6UUN3ME20O{41OTJ6IN88US=> NFjyXFBUSU6JRWK=
A3-KAW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR7LkiwOlEh|ryP MmHnV2FPT0WU
TC-YIK MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTVyLkCzOlMh|ryP MWPTRW5ITVJ?
SW962 NH3vVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nhcGlEPTB;NUSuPFM2PyEQvF2= NVzRdpJ4W0GQR1XS
KP-N-RT-BM-1 M2KxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0c2lKSzVyPUW2MlY3OzhizszN MXfTRW5ITVJ?
NCI-H1395 NVm1XIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTV6LkixO|Ih|ryP MmfBV2FPT0WU
RPMI-8402 NH\OeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzxOnhZUUN3ME21PE46PTJ4IN88US=> NFTvPIlUSU6JRWK=
SCH MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFuzTXhKSzVyPU[wMlk3OzhizszN M{TYUXNCVkeHUh?=
NCI-H2196 M3jD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZzLkKzNUDPxE1? NUfjcXVzW0GQR1XS
LOXIMVI NGPOT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTZzLkiyOlYh|ryP MXXTRW5ITVJ?
TGBC24TKB Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGwWVJKSzVyPU[yMlE1QTFizszN M2fxUnNCVkeHUh?=
SK-MEL-2 M1XvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZ|Lkm4PVIh|ryP MkfVV2FPT0WU
U-698-M MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HDVWlEPTB;NkiuOVY5PyEQvF2= M2r2bXNCVkeHUh?=
NCI-H1522 NHLJdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljUTWM2OD14OT6wNFQ4KM7:TR?= MmrGV2FPT0WU
UACC-812 NX3FfYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHTTWM2OD14OT61NlA6KM7:TR?= NYTmb3BpW0GQR1XS
MHH-CALL-2 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC5OYVKUUN3ME23NE4xPiEQvF2= NHPxcWdUSU6JRWK=
NB5 NELDPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHRWHN1UUN3ME23NE4{PDZ6IN88US=> MVLTRW5ITVJ?
KARPAS-299 NV2wPFZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf1TWM2OD15MD60OFQ4KM7:TR?= Mn7tV2FPT0WU
NCI-H1694 NILZXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTdzLkCzNkDPxE1? MmPXV2FPT0WU
NCI-H82 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTdzLkm1NFch|ryP MlnwV2FPT0WU
SCC-15 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHVOXRKSzVyPUeyMlM1KM7:TR?= M3LPTHNCVkeHUh?=
NCI-H1436 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjVTHZZUUN3ME23Nk44PDV4IN88US=> MlTUV2FPT0WU
ATN-1 M2fweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jNeWlEPTB;N{SuOVA2KM7:TR?= MYDTRW5ITVJ?
RPMI-8866 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7NTWM2OD15ND63OVA6KM7:TR?= Mnf3V2FPT0WU
HCC1599 NXzTcJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTd2Lki3N|Ih|ryP NGDi[mZUSU6JRWK=
NCI-H1155 M3e0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\NTWM2OD15ND65N|Y4KM7:TR?= M2DYU3NCVkeHUh?=
DOHH-2 NEiwfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TIS2lEPTB;N{SuPVUyPCEQvF2= MXLTRW5ITVJ?
SK-NEP-1 NWfuW|B3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fUN2lEPTB;N{WuNFc2PCEQvF2= NGDlOoRUSU6JRWK=
HCC1187 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[zTWM2OD15Nz62NVIzKM7:TR?= NH;PO2xUSU6JRWK=
NCI-H322M NVHQUmh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL1eldUUUN3ME23PE4{PzB7IN88US=> Ml7SV2FPT0WU
NCI-H526 NWrYVY5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL3WYNKSzVyPUe4MlU5PzdizszN M3rEO3NCVkeHUh?=
NCI-H2171 M{jPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL4ZZVKSzVyPUe5MlQyOzZizszN MlnVV2FPT0WU
COLO-668 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\jXWlEPTB;OEGuOVg5PCEQvF2= M1HpVHNCVkeHUh?=
RS4-11 M{js[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLMelJlUUN3ME24Nk4zPTB3IN88US=> MXnTRW5ITVJ?
NCI-H716 NFnRcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjk[HJ3UUN3ME24Nk46ODd3IN88US=> NHrRR4xUSU6JRWK=
LU-134-A MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTh|LkGzOVEh|ryP NFu1OWVUSU6JRWK=
RPMI-8226 M{\DT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13ESmlEPTB;OESuNlExPyEQvF2= MnLYV2FPT0WU
KY821 NHHaVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfLTWM2OD17MT62OVUyKM7:TR?= MWDTRW5ITVJ?
ECC4 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKzOoRKSzVyPUmzMlgzPjlizszN NYnCSoJ5W0GQR1XS
EW-3 MmnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz5VnVKSzVyPUm0MlkxQDFizszN MkHyV2FPT0WU
NB7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn6R4dKSzVyPUm1Mlc4QDZizszN NGDt[oRUSU6JRWK=
NCI-H720 NGf6SFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTl6LkSwOlEh|ryP NFLpUZdUSU6JRWK=
NCI-H446 M{\WXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK5PI5KSzVyPUm5Mlc2QDhizszN MYPTRW5ITVJ?
NCI-H889 M1jL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nIU2lEPTB;MUC0MlI1OiEQvF2= NXnSSItmW0GQR1XS
EW-22 M1PXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fKcWlEPTB;MUC2MlE6KM7:TR?= NF\nZXJUSU6JRWK=
BV-173 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK5TWM2OD1zMEiuO|I5KM7:TR?= M1LMSHNCVkeHUh?=
WSU-NHL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLwdnNbUUN3ME2xNFkvPjdzIN88US=> M2X1WHNCVkeHUh?=
MN-60 NHvpdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFyOT62PUDPxE1? M1\mWHNCVkeHUh?=
DG-75 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e4UGlEPTB;MUGzMlM2OiEQvF2= M1jPW3NCVkeHUh?=
DMS-79 M1rGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7icY1KSzVyPUGxO{4{QDJizszN NFjPcmpUSU6JRWK=
SK-MEL-1 NID4NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFzOD6wNFkh|ryP NUXnd5pzW0GQR1XS
DMS-153 M1;2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG1[JNKSzVyPUGyNU44PDVizszN MYfTRW5ITVJ?
NCI-H510A M2H3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzXTWM2OD1zMkeuN|Ih|ryP NV;a[I1nW0GQR1XS
BE-13 M4Pr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TjOWlEPTB;MUO0MlA1PCEQvF2= NFr0UWhUSU6JRWK=
KP-N-YS MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF|OT63N|Yh|ryP MnLTV2FPT0WU
SUP-T1 NFHQcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QNGlEPTB;MUSzMlcxQCEQvF2= NV3zOpF6W0GQR1XS
EW-12 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jVTGlEPTB;MUS0MlY6QSEQvF2= NVvaN5NIW0GQR1XS
NB14 NVK1SlR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTsTWM2OD1zNEeuNFgzKM7:TR?= Mm\sV2FPT0WU
MDA-MB-134-VI NULlZZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPib5dvUUN3ME2xOFgvOjZ6IN88US=> M1juWnNCVkeHUh?=
NCI-H1770 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF3Nj6yO|kh|ryP NFfpVXNUSU6JRWK=
TUR M2TTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHWTWM2OD1zNkeuPFch|ryP M1j5ZnNCVkeHUh?=
NCI-H1417 NGnlZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvNTWM2OD1zOECuN|MyKM7:TR?= NWDNUZBVW0GQR1XS
IMR-5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6MT61O|Eh|ryP NXLW[3B{W0GQR1XS
NCI-H226 NHGzTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;FV4tyUUN3ME2xPFgvQDZ4IN88US=> NXL3blRZW0GQR1XS
NCI-H187 NUXmOpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrvTWM2OD1zOUCuNFY1KM7:TR?= Mn:xV2FPT0WU
SF539 NVLKSZViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ze2pKSzVyPUG5Nk44OjhizszN MorwV2FPT0WU
TALL-1 NFzaTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnqbGlKSzVyPUG5PE4{ODRizszN MmnCV2FPT0WU
TE-441-T M4rsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7hOlhKSzVyPUG5PU44OzlizszN NF7mUoxUSU6JRWK=
REH MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ|Nj62NlYh|ryP M2rJbnNCVkeHUh?=
MS-1 M{f6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zyRWlEPTB;MkO5MlEzOSEQvF2= NIXpXWpUSU6JRWK=
THP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HEdWlEPTB;Mk[0Mlc{QCEQvF2= NHj2RllUSU6JRWK=
NCI-H1838 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ5MT60OVYh|ryP MmLqV2FPT0WU
P30-OHK M1fjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvXTWM2OD1{OEOuPFQ4KM7:TR?= M2fZUXNCVkeHUh?=
C8166 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u4XmlEPTB;M{S1MlM{QCEQvF2= NWTBWY97W0GQR1XS

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo

Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]
- Collapse

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]
- Collapse
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]
- Collapse
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Water Insoluble
Ethanol ''25 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing. 		2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5
CAS No. 1211877-36-9
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)CC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

selleck catalog

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

  • VR23 New

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin New

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.

  • Marimastat (BB-2516) New

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341, LDP-341, MLM341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.

  • Ixazomib (MLN2238)

    Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • Ixazomib Citrate (MLN9708)

    Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol (Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID